$APMD

SEKHRI PAUL J purchased $200K of APMD

SEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.

Original reporting
SEC EDGAR · SEKHRI PAUL J
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$APMD
Bullish
medium confidence
Mentioned
$APMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APMDBullishLow
01

Why it matters

A director open-market purchase of $200,000 is a new, time-specific datapoint but lacks accompanying fundamental disclosures (no guidance, trial, contract, or regulatory action mentioned).

02

Market read

Traders may note the insider buy as a small sentiment input, but the text provides no catalyst likely to drive a repricing on its own.

03

What to watch

The article does not state whether the director’s purchase was part of a broader pattern, nor does it provide context on total holdings, compensation, or any concurrent company news.

Relevance 5/10Novelty 5/10Timing: Filed 2026-08-03, after-hours/late session disclosure window

Background

The article is an SEC Form 4 insider transaction disclosure for Apnimed, Inc.

Company-level read

Ticker impact

$APMDBullishMedium confidence
Context

Apnimed director SEKHRI PAUL J bought 12,500 shares on 2026-08-03 at $16.00, totaling $200,000, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless accompanied by other company-specific news.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is a single director buy with no 10b5-1 plan and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-wide implications stated; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and do not guarantee near-term outperformance.

Key entities

  • Apnimed, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SEKHRI PAUL J

    Director who purchased 12,500 shares on 2026-08-03 at $16.00 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$APMDHigh

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Apnimed, Inc. (APMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update • U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28, 2027 • If approv

$APMDMedAI 8/10

Apnimed raises $220.8M in upsized Nasdaq IPO

Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.

$APMDMedAI 8/10

Apnimed Soars 56% in Nasdaq Debut After $192M IPO

Apnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.